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Abstract Heart failure is a life-threatening condition that
carries a considerable emotional and socio-economic burden.
As a result of the global increase in the ageing population,
sedentary life-style, increased prevalence of risk factors, and
improved survival from cardiovascular events, the incidence
of heart failure will continue to rise. Despite the advances in
current cardiovascular therapies, many patients are not suit-
able for or may not benefit from conventional treatments.
Thus, more effective therapies are required. Transforming
growth factor (TGF) β family of cytokines is involved in
heart development and dys-regulated TGFβ signalling is
commonly associated with fibrosis, aberrant angiogenesis
and accelerated progression into heart failure. Therefore, a
potential therapeutic pathway is tomodulate TGFβ signalling;
however, broad blockage of TGFβ signalling may cause
unwanted side effects due to its pivotal role in tissue homeo-
stasis. We found that leucine-rich α-2 glycoprotein 1 (LRG1)
promotes blood vessel formation via regulating the context-
dependent endothelial TGFβ signalling. This review will
focus on the interaction between LRG1 and TGFβ signalling,
their involvement in the pathogenesis of heart failure, and the
potential for LRG1 to function as a novel therapeutic target.
Keywords LRG1 . TGFβ . Cardiac remodelling .
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Introduction
Heart failure is a progressive and chronic condition in which
the heart is no longer able to circulate blood efficiently to meet
the body’s demands (Johnson 2014). A wide range of condi-
tions such as ischemic heart disease (IHD), hypertension,
valvular heart disease, myocarditis, diabetes and cardiomyop-
athy can lead to heart failure (Nishimura et al. 2014). In
response to stress or injury, the myocardium undergoes a
series of pathological changes including structural rearrange-
ment and morphological changes of cardiomyocytes, inflam-
mation, extracellular matrix (ECM) remodelling, microvascu-
lar rarefaction and chamber dilation (Manabe et al. 2002;
Kehat and Molkentin 2010). These changes cause further
deterioration in cardiac function and eventually lead to heart
failure (Cohn et al. 2000).
Over the last few decades, the prevalence and incidence of
heart failure continues to rise mainly due to the prolonged
longevity, improved survival rate from other cardiovascular
events (e.g., myocardial infarction, valvular disease, and ar-
rhythmias), sedentary life style, and the increased prevalence
of risk factors (e.g., hypertension, diabetes and obesity) (Mann
DL 2012). In 2010, more than 41 million people lived with
heart failure worldwide (Forouzanfar et al. 2013). Despite
improved understanding of the molecular mechanisms and
significant advances in treatment strategies, heart failure still
carries substantial morbidity and mortality and its therapy
remains a major unmet medical need. In this review, we
summarise the current knowledge on the role of TGFβ1 and
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its novel modulator, LRG1, in different pathologies of cardiac
remodelling and the potential of LRG1-targeted therapeutics
for the treatment of heart failure.
The challenges of current treatments for heart failure
Heart failure is a heterogeneous disease with a broad spectrum
of symptoms. Current treatments aim to alleviate symptoms,
slow disease progression and thereby improve overall quality
of life and survival. For example, IHD-induced heart failure,
the most common type of the disease, is normally treated with
antiplatelet drugs, anticoagulants and β-blockers. Emergent
reperfusion via surgical or catheter-based revascularisation
procedures is used to restore blood flow and improve survival
following ischemic episodes (Heuser et al. 2000; Horvath
2000). However, a substantial portion of patients are not
suitable for or do not benefit from conventional
revascularisation treatments because of a poor overall health
status or the presence of comorbidities (Norgren et al. 2007).
Even in patients who received successful primary
revascularisation, stent thrombosis and saphenous vein bypass
graft disease can occur and cause recurrent myocardial ische-
mia and cardiac remodelling (Kaul et al. 1991). Furthermore,
none of these treatments alters the natural history of heart
failure and therefore offers no cure.
Both human and animal studies have shown that individ-
uals with robust collateral circulation and microvascular per-
fusion are associated with delayed myocardial cell death
(Antoniucci et al. 2002), reduced occurrence of myocardial
infarction (MI) (Choi et al. 2013), smaller infarction size
(Habib et al. 1991) and increased survival (Meier et al.
2012). However, the capacity of collateral and capillary vessel
remodelling under ischemic condition is highly variable
among individuals. Accelerating this innate physiological re-
sponse by exogenous angiogenic factors has been considered
as an attractive approach to bypass occluded vessels,
revascularise ischemic tissues and restore tissue function
(Carmeliet and Jain 2011). An impressive body of pre-
clinical evidence has demonstrated improved myocardial per-
fusion and function upon therapeutic angiogenesis in animal
models (Harada et al. 1994; Unger et al. 1994; Landau et al.
1995; Lazarous et al. 1996; Shou et al. 1997; Lopez et al.
1998; Lee et al. 2000; Zhang et al. 2002; Cao et al. 2005;
Heinl-Green et al. 2005; Cao 2009). Initial phase I clinical
trials in patients with advanced IHD, but who did not meet the
criteria for standard revascularisation strategies, have also
demonstrated an improved cardiac circulation and function
after being treated with pro-angiogenic factors such as vascu-
lar endothelial growth factors (VEGF) and basic fibroblast
growth factor (bFGF) (Losordo et al. 1998, 2002; Schumacher
et al. 1998; Rosengart et al. 1999; Symes et al. 1999; Hendel
et al. 2000; Udelson et al. 2000; Henry et al. 2001; Vale et al.
2001; Fortuin et al. 2003; Reilly et al. 2005). However,
caution is needed in the interpretation of outcomes of these
studies as most of them lack proper placebo controls. Not
surprisingly, similar therapeutic efficacy has not yet been
achieved in larger, placebo-controlled, late-stage clinical tri-
als, which is partly due to the extent of angiogenesis observed
in the placebo group (Grines et al. 2002, 2003; Simons et al.
2002; Kastrup et al. 2011).
Angiogenesis is a tightly controlled process involving mul-
tiple levels of interactions between a wide variety of mole-
cules, cells and extracellular matrix (ECM) proteins. It is now
widely accepted that a single angiogenic factor may not be
sufficient to induce the formation of functional vasculatures.
Indeed, the treatment of VEGF leads to the formation of leaky,
chaotic and tortuous vessels that lack the normal hierarchical
structure (Nagy et al. 2007; Hedlund et al. 2009; Cao et al.
2010). Furthermore, both VEGF (Thurston 2002) and bFGF
(Cuevas et al. 1991) are involved in vessel dilation and their
treatment is associated with severe hypotension (Hariawala
et al. 1996; Horowitz et al. 1997; Unger et al. 2000; Henry
et al. 2001). In addition, there is evidence that VEGF exerts
detrimental pro-atherogenic effects by influencing endothelial
and immune cell function (Ross 1993; Inoue et al. 1998; Kim
et al. 2001). A combination treatment targeting growth factors
with complementary mechanismsmight be more effective and
has less unwanted side effects.
ECM is essential for proper cardiac function. It provides a
scaffold for different types of cells in myocardium and trans-
mits mechanical force and signals to myocardial fibres
(Banerjee et al. 2006). ECM remodelling is a critical step that
allows the ordered replacement of damaged cells after injury.
However, chronic inflammation and repetitive injury can
cause disturbed ECM homeostasis and fibrosis, a feature
shared by many conditions associated with heart failure (We-
ber et al. 1995). Cardiac fibrosis exaggerates mechanical
stiffness of the myocardium and its vasculature, impairs
myocyte contractility, disrupts electrical coupling, destroys
normal tissue architecture and eventually leads to heart failure
(Lopez et al. 2001; Ho et al. 2010; Karagueuzian 2011).
Increasing evidence shows that fibrosis is a dynamic and
reversible process (Iredale 2007). Targeting fibrosis, therefore,
presents a promising strategy to prevent or slow down the
deterioration of cardiac function. Despite its huge impact on
cardiovascular diseases and intensive research efforts to ex-
plore new therapies, there is no approved treatment that di-
rectly targets the mechanisms of fibrosis in the heart.
TGFβ1 and heart failure
The TGFβ family of cytokines plays important roles in em-
bryogenesis, tissue homeostasis and regeneration (Massague
2012). Their secretion, activation and function are tightly
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controlled by multiple mechanisms to ensure precise signal
propagation (Fig. 1). TGFβs are secreted in latent form as part
of a large protein complex (Khalil 1999) and their activation
requires functional and physical cooperation of mannose-6-
phosphate (M6P)/insulin-like growth factor II receptor
(IGFIIR), urokinase-type plasminogen activator receptor
(UPAR), Neuropilin 1 (NRP1) and different proteases and
metalloproteases (MMPs) (Dennis and Rifkin 1991; Scott
and Firth 2004; Glinka et al. 2011; Shi et al. 2011). Once
released, TGFβs bind to type II receptor TGFβRII, which
recruits type I receptor, activin receptor-like kinase (ALK)
(Shi and Massague 2003), and activates a multitude of intra-
cellular signalling including canonical Smad and non-
canonical ERK, JNK, TAK1, P38 and Rho cascades (Derynck
and Zhang 2003). TGFβs also interact extensively with other
signalling pathways leading to very different even opposite
outcomes (Massague 2012).
In mammals, there are three different isoforms: TGFβ1,
TGFβ2, and TGFβ3. Each of them shows distinct expression
pattern and functions. TGFβ1, the focus of this review, is the
predominant and most ubiquitously expressed isoform
(Millan et al. 1991). In the heart, TGFβ1 regulates the signal-
ling and function of different types of cells, including endo-
thelial cells (ECs), vascular mural cells (pericytes in capillaries
and vascular smooth muscle cells (VSMCs) in larger vessels),
myofibroblasts, macrophages and cardiomyocytes (Bujak and
Frangogiannis 2007; Koitabashi et al. 2011). Aberrant TGFβ1
signalling contributes to the development of a multitude of
Fig. 1 Schematic representation of TGFβ signalling and crosstalk with
other signalling pathways. TGFβ ligands are synthesised as a large latent
complex consisting of TGFβ dimmer covalently associated with a
latency-associated peptide (LAP) and a latent TGFβ-binding protein
(LTBP). The activation of latent TGFβ requires functional and physical
cooperation of M6P/IGFIIR, UPAR, NRP1 and other proteases and
MMPs. The released TGFβ dimers bind the type II TGFβ receptor
(RII) first, which recruits and transphosphorylates the type I receptors
(RI). RI propagates the signal into the cell by phosphorylating TGFβ
receptor-regulated SMADs (R-Smads). They form heteromeric com-
plexes with the common SMAD (co-Smad) and translocate to the nucle-
us. The R-Smads–co-Smad complex formation can be inhibited by
inhibitory Smad (I-Smad). Once in the nucleus, the R-SMAD–co-SMAD
complex associates with other DNA-binding transcription factors to
modulate the expression of target genes. In the non-canonical pathways,
the activated transforming growth factor-β (TGFβ) receptor complex
transmits a signal through other factors, such as TGFβ-activated kinase
1 (TAK1), p38 mitogen-activated protein kinase (p38 MAPK), RHO,
phosphoinositide 3-kinase (PI3K)–AKT, extracellular signal-regulated
kinase (ERK), Rho-associated protein kinase (ROCK), or JUN N-
terminal kinase (JNK). TGFβ signalling interacts extensively with other
pathways, such as the WNT, Notch, AngII, IGF and VEGF pathways,
which defines the context-dependent TGFβ signalling
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conditions associated with heart failure such as dilated and
hypertrophic cardiomyopathies, post-infarction myocardial
remodelling, valvular diseases and arrhythmia in both mice
and humans (Cambien et al. 1996; Schultz Jel et al. 2002;
Euler-Taimor and Heger 2006; Khan and Sheppard 2006;
Kapur et al. 2013).
TGFβ1 and cardiac fibrosis
TGFβ1 is a potent fibrogenic factor that mediates ECM
homeostasis through different mechanisms, for example,
by inducing ECM (such as collagens and fibronectin) syn-
thesis via both canonical and non-canonical signalling
cascades (Chen et al. 2000; Qiao et al. 2005; Leask
2007), decreasing the production of proteinase regulating
ECM degradation (such as MMPs), promoting the produc-
tion of inhibitors of these proteases (such as TIMPs)
(Biernacka et al. 2011) and promoting integrin expression
to increase the adhesion of cells to matrix (Thannickal
et al. 2003). Studies have shown that TGFβ1 signalling
pathway components, including TGFβ1, ENG and Smads,
are markedly up-regulated at the site of injury after MI
(Hao et al. 1999; Krum et al. 2002; Dean et al. 2005; Kapur
et al. 2012), in patients suffering from hypertrophic car-
diomyopathy (Villarreal and Dillmann 1992, Li et al. 1998)
and dilated cardiomyopathy (Pauschinger et al. 1999;
Sanderson et al. 2001), and all these conditions are
characterised by excessive fibrosis in the heart. Consistent-
ly, TGFβ1 overexpression in transgenic mice leads to
myocardial fibrosis (Rosenkranz et al. 2002; Seeland
et al. 2002). Studies have shown that TGFβ1-mediated
endothelial-to-mesenchymal transition (EndoMT) also
contributes to myocardial fibrosis (Zeisberg et al. 2007;
van Meeteren and ten Dijke 2012). Recently, ENG, a
previously considered EC specific TGFβ1 receptor, has
been found to be expressed in cardiac fibroblasts and to
mediate the pro-fibrotic effect of angiotensin II (AngII) via
angiotensin II receptor type 1 (AT1) (Chen et al. 2004).
Reduced ENG activity led to attenuated cardiac fibrosis
and increased survival in an in vivo model of heart failure
(Kapur et al. 2012). This study demonstrated that the
expression of ENG is significantly up-regulated in human
failing left ventricles. Inhibition of the activity of ENG-
attenuated TGFβ1 induced Smad2/3 phosphorylation,
ECM deposition and cardiac fibrosis. Eng+/− mice with
pressure overload-induced heart failure showed an in-
creased capillary density in the heart, preserved cardiac
function and improved survival. Thus, targeting the
TGFβ1 signalling pathway might provide an attractive
strategy to limit structural deterioration of myocardium
and ultimately lead to improved cardiac function, and
survival of heart failure patients.
TGFβ1 and cardiomyocyte hypertrophy
In addition to fibrosis, hypertrophic growth of cardiomyocytes
occurs in response to haemodynamic overload and represents
the heart’s effort to maintain cardiac output sufficient to meet
the body’s demands (Glennon et al. 1995). There is compel-
ling evidence that TGFβ1 plays a critical role in this process.
Increased TGFβ1 expression is observed in the myocardium
of human patients with idiopathic hypertrophic cardiomyopa-
thy (Li et al. 1998). Consistently, TGFβ1 overexpression in
transgenic mice results in hypertrophic growth of
cardiomyocytes (Rosenkranz et al. 2002). Interestingly, this
TGFβ1-induced cardiac hypertrophy is associated with in-
creased myocardial β-adrenergic receptors (ARs) density
(Rosenkranz et al. 2002) and β-AR blockade treatment in
TGFβ1 transgenic mice prevents cardiac hypertrophy. On
the other hand, angiotensin II was shown to induce TGFβ1
expression in myocardium and TGFβ1 (Wenzel et al. 2001) is
required for AngII-mediated cardiacmocyte hypertrophy
(Gray et al. 1998). However, the AT1 receptor blockade is
insufficient to prevent the hypertrophic response in TGFβ
transgenic mice (Rosenkranz et al. 2003), and TGFβ1 knock-
out mice are resistant to AngII-induced cardiac hypertrophy
(Schultz Jel et al. 2002). Together, these data show that
TGFβ1 plays a key role in AngII-mediated growth responses
of cardiomyocytes via β-AR.
TGFβ1 and post-infarction inflammatory response
Cardiomyocyte death and hypoxia following infarction initi-
ate inflammatory response, which leads to the infiltration of
immune cells into the infarcted area, an important process for
clearing debris from the wound and tissue repair (Mehta and
Li 1999). In the meantime, a timely repression of inflamma-
tory mediator synthesis is important for scar maturation.
TGFβ1 plays a highly important and complex role in inflam-
matory response following cardiac injury (Celada and Maki
1992), It acts as a direct chemoattractant to monocytes (Wahl
et al. 1987) and neutrophils (Fava et al. 1991) to recruit them
to the infarct site. However, its effects on macrophages are
primarily inhibitory (Frangogiannis et al. 2001). There is a
need for a better understanding of the TGFβ1-modulated
post-infarction inflammatory response for specific interven-
tion that could attenuate inflammatory injury without interfer-
ing with myocardial healing.
TGFβ1 and cardiac neovascularisation
Genetic studies in mouse and human revealed that proper
TGFβ1 signalling is essential for blood vessel formation
(Chang et al. 2001; Harradine and Akhurst 2006). The
vascular response to TGFβ1 is highly context-dependent
and is shaped by factors such as ligand bioavailability and
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concentration, receptor availability and internalization,
cross-talk with other signalling pathways, micro/
marcovessel origin of vascular cells, and cellular density
(Massague 2012). Although not fully understood, it is gen-
erally considered that TGFβ1 signalling in ECs occurs
through TGFβRII recruiting either the ubiquitously
expressed ALK5 or the EC-specific ALK1 (possibly with
ALK5). Signalling via ALK5 leads to the activation of
downstream transcription factors Smad 2 and 3, and thus
plays an essential role in maintaining the vasculature at
quiescent state. The TGFβ1/ALK1 signalling activates
Smad 1, 5 and 8, resulting in increased EC migration,
proliferation and angiogenesis (Goumans et al. 2003). The
two pathways interact with each other at both receptor and
the Smad level (Goumans et al. 2003), with ENG as a key
player in switching TGFβ signalling toward the pro-
angiogenic pathway (Lebrin et al. 2004). This paper
showed that ENG regulates the balance of TGFβ signalling
in endothelial cells by promoting TGFβ/ALK1 and
inhibiting TGFβ/ALK5 signalling, and the subsequence
endothelial proliferation.
Besides ECs, blood vessels comprise another essential
component. The vascular mural cells support endothelium
and are involved in blood vessel maturation and homeosta-
sis. Similar to that in ECs, TGFβ1 mediates the prolifera-
tion of VSMC in a dose-dependent manner with high-dose
being inhibitory and low-dose being stimulatory (Seay et al.
2005; Tsai et al. 2009). TGFβ1 induces the contractile
phenotype of VSMCs by promoting the expression of α-
smooth muscle actin and smooth muscle myosin
(Hautmann et al. 1997; Seay et al. 2005). Perturbed TGFβ1
signalling results in failure of VSMC recruitment (Pardali
et al. 2010) and the formation of aneurysm (Choudhary
et al. 2009). TGFβ1 also stimulates the expression of plas-
minogen activator inhibitor (PAI)-1, a potent inhibitor of
matrix MMPs, and therefore promotes blood vessel matu-
ration by preventing the degradation of provisional matrix
surrounding the nascent vessel (Jain 2003). On the other
hand, the juxtaposition and collaboration between mural
cells and ECs are important for local activation of latent
TGFβ1, which further defines its context-dependent sig-
nalling in vascular cells (Antonelliorlidge et al. 1989; Sato
et al. 1990).
Together, extensive investigations have shown that
TGFβ1 modulates the signalling and function of different
vascular cells and participates in multiple stages of blood
vessel development, which makes it an attractive target for
therapeutic angiogenesis. Indeed, it has been reported that
exogenous application of TGFβ1 stimulates blood vessel
formation in peripheral circulation (van Royen et al. 2002).
This study showed that exogenous TGFβ1 promotes pe-
ripheral collateral artery formation and collateral circula-
tion in rabbit hind limb model of femoral artery occlusion,
partly by increasing monocyte adhesion and transmigration
and enhancing the expression of growth factors and cyto-
kines. Further studies are required to evaluate the impact of
TGFβ treatment on functional blood vessel formation in the
heart.
TGFβ1 signalling as a therapeutic target for heart failure?
TGFβ1 coordinates a broad spectrum of cellular processes
that contributes to cardiac remodelling after MI and subse-
quent progression to heart failure (Bujak and Frangogiannis
2007). It can be beneficial or deleterious depending on the
stage of disease development. For example, TGFβ1 plays a
pivotal role in wound repair after infarction by suppressing
inflammation, promoting the myofibroblast transition, and
inducing blood vessel remodelling (Dobaczewski et al.
2011). However, prolonged TGFβ activation leads to ex-
cessive ECM deposition remote from the infarct site caus-
ing further damage to normal tissue architecture and cardiac
function (Bujak et al. 2007). Indeed, inhibition of TGFβ
before or immediately following MI led to further deterio-
ration on cardiac function and increase mortality (Ikeuchi
et al. 2004; Frantz et al. 2008), whereas its inhibition at 24 h
post-MI attenuated remodelling with improved cardiac
function in animal models of ischemic heart failure (Ikeuchi
et al. 2004; Okada et al. 2005; Ellmers et al. 2008). In
addition, due to its multifunctional and context dependent
actions, a complete blockage of TGFβ signalling may
cause undesirable side effects on immune regulation
(Sasaki et al. 1992), angiogenesis (Bertolino et al. 2005),
cancer surveillance (Salomon 2014) and wound healing
(Faler et al. 2006). Taken together, TGFβ-targeted treat-
ment must be carefully designed. A strategy that selectively
attenuates the fibrogenic effect but stimulates the pro-
angiogenic aspect of TGFβ1 may serve as an ideal treat-
ment option for heart failure.
The interaction between LRG1 and TGFβ signalling
Leucine-rich α-2 glycoprotein 1 (LRG1) is a member of
leucine-rich repeat (LRR) family of proteins, many of which
are involved in protein–protein interactions, signalling and
cell adhesion (Ng et al. 2011). Studies have shown that dif-
ferential expression of LRG1 is associated with different types
of cancer (Kawakami et al. 2005; Kakisaka et al. 2007; Ferrero
et al. 2009; Andersen et al. 2010; Guergova-Kuras et al. 2011;
Li et al. 2011; Sandanayake et al. 2011; Ladd et al. 2012;
Linden et al. 2012, 2013; Liu et al. 2012; Wu et al. 2013; He
et al. 2014; Wen et al. 2014), neurodegenerative disease
(Miyajima et al. 2013), inflammatory diseases (Kentsis et al.
2012; Kharbanda et al. 2012; Serada et al. 2012),
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hydrocephalus (Li et al. 2006, 2007; Nakajima et al. 2010,
2011), heart failure (Watson et al. 2011), autoimmune disease
(Serada et al. 2010), and ageing (Nakajima et al. 2012)
We found recently that LRG1 is expressed in quiescent
vasculature at low levels but is significantly up-regulated
together with TGFβ1 in remodelled and neovascular ves-
sels in the eye (Wang et al. 2013). We showed that LRG1
interacts with multiple TGFβ receptors, especially ENG,
which together with TGFβ1 further promotes the ability of
LRG1 to bind angiogenic ALK1 but inhibits the association
between LRG1 and angiostatic ALK5. The recruitment of
LRG1 into the pro-angiogenic TGFβ receptor complex
leads to enhanced Smad 1, 5 phosphorylation, EC prolifer-
ation, tube formation and blood vessel outgrowth. LRG1
inhibition by genetic knockout, siRNA knockdown or neu-
tralizing antibodies led to reduced angiogenesis. In sum-
mary, our study showed that LRG1 plays a critical role in
defining the context-dependent TGFβ signalling in ECs
(Wang et al. 2013).
There is evidence that LRG1 is involved in other TGFβ-
regulated processes. TGFβ is known to stimulate the ex-
pression of endothelin (ET1) (Ahmedat et al. 2012), an
important molecule involved in myocardial hypertrophy
and fibrosis. ET1 has been shown to inhibit LRG1 expres-
sion in dermal fibroblasts suggesting a potential role of
LRG1 in TGFβ-mediated fibrosis (GEO accession
GDS1980 / 1417290_at / Lrg1) (Vallender and Lahn
2006).
The involvement of LRG1 in cardiac remodelling
and heart failure
LRG1 and ageing heart
As an unavoidable process of life, different systems of the
body undergo progressive structural and functional alter-
ations, and the heart is not an exception. With ageing, there
is increased plaque formation in coronary arteries, cardiac
wall thickness and interstitial fibrosis (Mendes et al. 2012;
Dayal et al. 2013). These structural changes of myocardi-
um are accompanied with concurrent vascular abnormali-
ties, such as reduced diameter and density of collateral
vessels, decreased vasodilation, and increased stiffness of
vessel walls (Heil and Schaper 2004; Faber et al. 2011;
Wang et al. 2011). In addition, there is a decreased expres-
sion and availability of growth factors such as hypoxia-
inducible factor 1α and VEGF in response to hypoxic
stress (Rivard et al. 2000), and ECs become less responsive
to the stimulation of angiogenic growth factors with ageing
(Lahteenvuo and Rosenzweig 2012). These alterations
contribute to compromised cardiac function, increased sus-
ceptibility to damage and reduced ability to repair, which
subsequently lead to increased incidence of heart failure in
ageing population. Two separate studies have reported an
decreased expression of LRG1 in the heart of aged mice
compared to that in young mice (GDS2996 / 1417290_at /
Lrg1 and GDS2972 / 97420_at / Lrg1) (Reiter et al. 2007).
However, it is not clear whether the reduced LRG1 expres-
sion is the cause or the consequence of ageing-related
structural and functional changes in the heart. Further
studies are required to explore the role of LRG1 in specific
patho-physiologies of the ageing heart and to discover
whether it is possible to prevent or reverse age-dependent
deterioration of the heart by overexpressing LRG1.
LRG1 and cardiac hypertrophy
Cardiac hypertrophy is the thickening of the heart wall in
response to increased pressure or volume stress. Under
certain conditions, such as during pregnancy or after
sustained exercise, the enlargement of heart muscle is
beneficial and is normally associated with a proportional
increase in chamber dimensions and neovascularization
(Catalucci et al. 2008). There is no concurrent fibrosis
or reactivation of a foetal gene program in this physio-
logical adaptation process (Beisvag et al. 2009). In addi-
tion, physiological hypertrophy does not cause increased
risk of arrhythmia, impairment in cardiac function or
future heart failure. Instead, exercise training has been
shown to protect the heart against ageing-induced up-
regulation of collagen deposition, collagen cross-linking,
TIMP synthesis and down-regulation of active MMPs
(Thomas et al. 2000, 2001; Kwak et al. 2008). The
ageing-associated increase in extra-myocyte space was
also significantly attenuated in rats which underwent ex-
ercise training (Kwak et al. 2008, 2011). Pathological
cardiac hypertrophy, on the other hand, occurs as a con-
sequence of hypertension, aortic stenosis, or other
disease-causing stimuli. It is associated with significant
structural abnormalities, which can lead to contractile
dysfunction, arrhythmias and eventually heart failure
(Scheuer et al. 1982; Breisch et al. 1986).
The activation of insulin-like growth factor-1 (IGF-1)/
phosphoinositide 3-kinase (PI3K)/Akt pathway has been
implicated in adaptive cardiac hypertrophy with endur-
ance exercise (Neri Serneri et al. 2001). Studies have
shown that transient activation of Akt1 leads to reversible
cardiac hypertrophy, which is associated with reduced
expression of Lrg1 (GDS2304 / 1417290_at / Lrg1)
(Schiekofer et al. 2006). Consistent with this observation,
a dominant negative form of PI3K significantly attenuates
cardiac hypertrophy in the heart of transgenic mice over-
expressing IGF1 receptor, which is also associated with a
concurrent up-regulation of Lrg1 (GDS648 / 97420_at /
Lrg1) (McMullen et al. 2004). However, a separate study
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showed no change in Lrg1 expression in transgenic mice
with either constitutive active PI3K or dominant negative
PI3K (GDS446 / 97420_at / Lrg1). Also, no change in
Lrg1 expression was detected in the heart of rats follow-
ing moderate physical training (GDS3134/1374626_at/
Lrg1) (Giusti et al. 2009). These seemingly contradictory
observations might be due to differences in the design of
transgenic strategies, spatial and temporal expression pat-
tern of transgenes, and the use of different animal species.
Further studies are required to elucidate the role of LRG1
in physiological cardiac hypertrophy.
A reduced expression of LRG1 is observed in mouse
models of pathological cardiac hypertrophy. LRG1 ex-
pression is significantly attenuated in the heart of mice
with compensated pressure overload hypertrophy induced
by transverse aortic constriction (TAC) (GDS794 /
97420_at / Lrg1, GDS3465 / 1417290_at / Lrg1) (Zhao
et al. 2004; Smeets et al. 2008). A missense E180G
mutation in α-tropomyosin (TM), an important contrac-
tile protein involved in sarcomeric function, is associated
with familial hypertrophic cardiomyopathy (Chang et al.
2005). Transgenic mice overexpressing α-TM E180G
exhibit severe cardiac hypertrophy characterized by
myocyte disarray, asymmetric ventricular enlargement,
fibrosis, cardiac arrhythmia and eventually die of heart
failure (Michele et al. 2002). The expression of Lrg1 is
significantly down-regulated in the ventricle of α-TM
E180G transgenic mice (GDS2134 / 1417290_at / Lrg1)
(Rajan et al. 2006).
Together, the literature supports lower LRG1 expression
being associated with cardiac hypertrophy. Further studies
are required to investigate the underlying molecular mech-
anism. Analysis of cardiac phenotypes in Lrg1−/− with
exercise or pressure overload-induced hypertrophy will
provide valuable information regarding the role of LRG1
in physiological and pathological cardiac hypertrophy.
LRG1 overexpression might be able to reverse cardiac
hypertrophy induced by the activation of IGF1/PI3K/
Akt1 pathway, exercise, pressure overload, and in α-TM
E180G transgenic mice. The activation of latent TGFβ
requires functional and physical cooperation of mannose-
6-phosphate (M6P)/IGF II receptor (IGFIIR) and the
urokinase-type plasminogen activator receptor (uPAR)
(Leksa et al. 2005). Furthermore, both TGFβ1 and IGF1
signal through the PI3K/Akt pathway and there is an ex-
tensive crosstalk between the two signalling pathways
during cardiac fibrosis (Butt et al. 1995), cardiomyocyte
apoptosis (Hynes et al. 2009), cardiac remodelling follow-
ing myocardial infarction (Stavropoulou et al. 2010) and
cardiac hypertrophy (Lisa et al. 2011). Understanding the
role of LRG1 in TGFβ1 and IGF1 interactions may shed
new light on the molecular mechanism of cardiac
hypertrophy.
LRG1 and dilated cardiomyopathy
Muscle LIM protein (MLP) is a muscle-restricted cyto-
skeletal binding protein. The down-regulation of MLP
protein is observed in human patients with idiopathic-
dilated cardiomyopathy (Zolk et al. 2000). Consistent
with this observation, MLP−/− mice develop dilated car-
diomyopathy and eventually heart failure (Arber et al.
1997). Calsequestrin (CSQ) is a high-capacity sarcoplas-
mic reticulum Ca2+ binding protein. The myocardial-
targeted overexpression of CSQ also leads to heart failure
associated with dilated cardiomyopathy and left ventricu-
lar dysfunction (Jones et al. 1998). Both mouse models
exhibited many key features present in the failing heart in
human, such as functional β-AR uncoupling (Rockman
et al. 1998). Advanced heart failure is normally developed
in 6-month old MLP−/− mice and 14-week old CSQ trans-
genic mice. Despite different aetiologies, a decreased
Lrg1 expression is associated with deterioration of cardiac
function with lowest Lrg1 expression observed at the
advanced stage of heart failure in both mouse models
(GDS411 / aa172851_s_at / Lrg1) (Blaxall et al. 2003).
However, the molecular basis of LRG1 down-regulation
in both mouse models remains to be resolved, which is
vital for dissecting the mechanism of dilated cardiomyop-
athy pathogenesis. LRG1 overexpression in myocardium
might restore cardiac function and slow down the pro-
gression of heart failure in both models. Information
extracted from this study will assist the designing effec-
tive treatment for dilated cardiomyopathy associated heart
failure.
LRG1 and hypertension
Hypertension is a major risk factor for heart failure. To
work against the high pressure, the heart must pump harder,
which may lead to left ventricular hypertrophy and heart
failure over time. The S.LWEx12x2x3x5 congenic rat is a
model for hypertension and exhibits concentric cardiac
hypertrophy. The expression of LRG1 is significantly
down-regulated in the left ventricle of hypertensive
S.LWEx12x2x3x5 rat exhibiting concentric cardiac hyper-
trophy with augmented contractile function (GDS3873 _
1374626_at _ Lrg1) (Gopalakrishnan et al. 2011). Howev-
er, it is not clear whether hypertension has a direct impact
on the expression of Lrg1 or mediates LRG1 expression
indirectly via hypertension-induced compensation. To
study the expression of Lrg1 in other hypertension animal
models with or without myocardial abnormalities will en-
rich our understanding of direct association between LRG1
and hypertension aetiology and development. LRG1 over-
expression at the right dosage and right timing might
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prevent or reverse hypertension and hypertension-induced
cardiomyopathy.
Perspectives
There is compelling evidence to suggest that TGFβ1 is
associated with various cardiac pathologies involved in
heart failure. Targeting TGFβ1 therefore represents an
attractive strategy in managing progression of the disease.
A number of therapeutic approaches for blocking the ac-
tions of TGFβ1 have been suggested, such as TGFβ1
neutralizing antibody (Kuwahara et al. 2002), soluble
TGFβ receptor II (Okada et al. 2005), and small molecule
inhibitors (Engebretsen et al. 2014). Some of these suc-
cessfully attenuated cardiac fibrosis, decreased ventricular
chamber dilation, improved cardiac function, and reduced
mortality after infarction in preclinical studies (Kuwahara
et al. 2002; Ellmers et al. 2008; Lian et al. 2010). However,
given its role in angiogenesis, targeting TGFβ may affect
collateral and microvessel formation, remodelling and per-
fusion following MI and cause increased burden of ische-
mic tissue. In addition, TGFβ1 is a pleiotropic cytokine
with vital homeostatic functions. Broad TGFβ inhibition is
likely to have adverse side effects, such as the development
of autoimmune diseases, delayed wound healing, and tu-
mour formation. Selectively targeting specific disease-
driving aspects of TGFβ signalling at the right dose and
timing and for an appropriate period is therefore critical in
producing desirable therapeutic effects.
Our recent study led to the identification of a novel angio-
genic factor, LRG1. In addition to ECs, LRG1 is also
expressed in cardiac fibroblasts (Ifkovits et al. 2014) and
cardiomyocytes (Chen et al. 2004). It is likely that LRG1
mediates TGFβ signalling through the ubiquitously expressed
type I TGFβ receptor, ALK5, in non-ECs. There is convinc-
ing evidence that a decreased expression of LRG1 is
Fig. 2 Potential role of LRG1 in cardiac remodelling. In the failing heart,
the ability of blood vessels to respond to angiogenic factors is
compromised, fibroblasts acquire myofibroblast phenotype by
expressing increased ECM protein, and cardiomycytes are enlarged and
undergo increased apoptosis. TGFβ1 mainly signals through ALK5 in
ECs, cardiomyocyte and myofibroblasts leading to cardiac remodelling.
In LRG1-treated heart, LRG1 switches TGFβ1 signalling towards the
proangiogenic ALK1 signalling in ECs and promotes blood vessel for-
mation. In myofibroblasts, LRG1 competes with TGFβ to bind ALK5
and antagonise TGFβ-induced ECM synthesis and to prevent fibrosis.
With the presence of LRG1, there is reduced cardiomyocyte apoptosis
and size
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associated with increased fibrosis, aberrant vascular proper-
ties, and altered cardiomyocytes characteristics in ageing
heart, and in failing heart induced by genetic modification,
pressure overload, or hypertension (Fig. 2). Understanding the
molecular mechanism underlying the role of LRG1 and its
regulation in cardiac remodelling process will assist the de-
velopment of novel treatments for heart failure.
LRG1, a potential target for therapeutic angiogenesis
LRG1 promotes EC proliferation, tube formation and vessel
outgrowth through regulating the endothelial TGFβ signalling
(Wang et al. 2013). As it binds to the ubiquitously expressed
type I TGFβ receptor, ALK5, LRG1 might mediate the sig-
nalling and function of other types of vascular cells and
regulate blood vessel remodelling. TGFβ1 interacts with
VEGF signalling at the receptor level (Glinka et al. 2011)
and regulates VEGF expression in macrophages (Jeon et al.
2007) and ECs (Ferrari et al. 2006). Understanding the role of
LRG1 in TGFβ1 and VEGF crosstalk may provide valuable
information regarding the molecular mechanism of angiogen-
esis, and facilitate the development of novel therapeutic an-
giogenesis strategies. Angiogenic factors are normally re-
leased in a tightly controlled and timely manner. Lessons
learned from previous studies suggested that the hypoxia
condition of the ischemic tissue during treatment dramatically
affects the benefit of therapeutic angiogenesis. Virus-based
transgene delivery systems offer an opportunity for site-
specific administration at the right location, time and dose.
The route of delivery may also affect the efficacy of treatment.
Direct delivery to the myocardium may be an effective meth-
od for therapeutic angiogenesis in the heart. Comorbidities are
known to have a great impact on the outcome of therapeutic
angiogenesis. It is therefore important to evaluate the impact
of LRG1 on angiogenesis under heart failure-associated dis-
ease conditions such as diabetes, hypertension and obesity. As
oedema can impose further burdens on ischemic tissue, stud-
ies are required to investigate the impact of LRG1 on blood
permeability. It is worth noting that excessive angiogenesis
contributes to cancer growth and metastasis, atherosclerotic
plaque expansion and instability, arthritis and blinding eye
diseases. Understanding the involvement of LRG1 in other
vascular complications will help to predict potential side
effects of the treatment. Taken together, LRG1 is an attractive
target for therapeutic angiogenesis. Further studies are re-
quired to evaluate the efficacy and toxicity of LRG1 treatment
for heart failure.
LRG1, a potential modulator of cardiac remodelling process
Cardiac fibrosis is a key contributor to the morbidity and
mortality in heart failure. Despite intense research efforts, no
effective treatment is available to control this detrimental
process. Evidence showed that a reduced expression of
LRG1 is associated with an increased TGFβ1 activity during
the cardiac remodelling process in response to injury. How-
ever, it is not clear whether TGFβ1 exerts its function by
inhibiting the expression of LRG1. As LRG1 binds ALK5
and TGFβRII independently of TGFβ1, it may exert its
function by competing with TGFβ1 for binding with the
ALK5/TGFβRII receptor complex. In addition to its role in
mediating TGFβ1 signalling in endothelial cells, ENG plays
an important role in cardiac fibrosis (Kapur et al. 2012).
Unveiling the interaction between ENG and LRG1 in fibrosis
will advance our understanding of the molecular mechanism
underlying the cardiac remodelling process. It is widely ac-
cepted that context-dependent TGFβ1 signalling is defined by
extensive interaction with other signalling pathways including
IGF1 and AngII. Understanding the involvement of LRG1 in
this highly complex network will shed light on the molecular
mechanism of cardiac remodelling. Studies have shown that
non-ECs including cardiac fibroblasts and cardiomyocytes
also express LRG1. It will be interesting to see novel binding
partners of LRG1 in these cells, and it will help to elucidate the
TGFβ1-independent role of LRG1 in non-ECs in the heart.
On the other hand, ECM is important for maintaining athero-
sclerotic plaque stability. Augment of collagen degradation
has been correlated with ruptured plaques in patients (Cheng
et al. 2009). Further studies are required to unveil the molec-
ular and cellular mechanism of LRG1 in atherosclerotic
plaque development and progression, which will provide
valuable insights into the potential side effects of LRG1-
targeted treatment.
Summary
At the moment, the focus of heart failure treatment is directed
at risk factor management and alleviating symptoms; howev-
er, not all patients are suitable or will benefit from current
therapeutics. As the magnitude of heart failure continues to
accelerate globally, there is a pressing need for new treat-
ments. Direct intervention on structural abnormalities of myo-
cardium is a promising strategy. A reduced expression of
LRG1 is associated with cardiac remodelling characterised
by hypertrophy, fibrosis, and abnormal vasculature in various
conditions leading to heart failure. However, it is not clear
whether altered LRG1 expression is the cause or the conse-
quence of these detrimental processes, or how LRG1 is cor-
related with specific pathologies and evolution of the disease.
Although a great deal of work is still needed to fully under-
stand the underlying mechanisms, targeting LRG1 and its
regulators might offer a unique approach to treating heart
failure by simultaneously targeting different pathologies of
the disease.
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